A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naive Locally Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naive Locally Advanced or Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PISCES
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 28 Apr 2016 The study is "Completed" in Finland, Germany, and Italy.
    • 03 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top